| خلاصه مقاله | Introduction: An imbalance in the regulation of the wound healing mechanism may result in the emergence of different types of persistent ulcers or abnormal excessive scarring. Hence, it is crucial to discover innovative pharmaceutical approaches for enhancing wound healing and reinstating the structural stability of damaged tissue. Nitric oxide assumes a pivotal function in overseeing three primary components of the wound healing process: vascular homeostasis, inflammation, and antimicrobial activity. The goal of the present study was to evaluate a novel M1 analogue with modified properties as compared to Melittin in the production of nitric oxide (NO) related to wound healing.
Materials and method: 84 Six‐week Balb/c male mice (18–23 g) were obtained from the animal facility, Tabriz university of medical science. Mice were randomly divided into six categories (n=14 per category) including the control group, the witness, the phenytoin group, the bee venom group, the Melittin group, and the M1 peptide group. The assessment of wound healing progress was conducted on the 7th and 14th days. NO production levels were assessed by biochemical analyses.
Results: Based on results, a significant percentile of wound healing was found in Melittin analog group. Based on NO analysis result, the treatment of mice with melittin and M1 analog ointments significantly increased the NO level compared to control and bee venom groups.
Discussion: Our findings highlight the therapeutic application of Melittin and Melittin analog in wound healing. |